2024-03-29T15:06:45Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:02001659
2023-11-16T01:56:33Z
499:508:509:1638493189962
Is area under the curve the best parameter for carboplatin induced emetic risk stratification?
Ozone, Sachiko
Ichikawa, Kazuya
Morise, Masahiro
Matsui, Akira
Kinoshita, Fumie
Matsuzawa, Reiko
Koyama, Junji
Tanaka, Ichidai
Hashimoto, Naozumi
open access
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
carboplatin
chemotherapy-induced nausea and vomiting (CINV)
moderate emetic risk regimen
antiemetic treatment
antiemetic guideline recommendations
Carboplatin (CBDCA)-induced emetic risk is currently classified on the basis of CBDCA-area under the curve (CBDCA-AUC). We investigated the utility of three CBDCA dosage parameters for predicting emesis by CBDCA. Patients with thoracic cancer treated with CBDCA were included. The endpoints were complete response (CR) and total control (TC). CR was defined as no vomiting and no use of rescue medication during the overall assessment period, whereas TC was defined as no vomiting, nausea, nor use of rescue medication during the overall assessment period. The parameters of CBDCA were defined as follows: (1) CBDCA-AUC; (2) CBDCA/body surface area (BSA): the administered dose of CBDCA per body surface area (mg/m2); and (3) total CBDCA/body: the total administered dose of CBDCA (mg). Eighty-five patients were evaluated. The median CBDCA/BSA but not CBDCA-AUC was higher in patients with non-CR compared to those with CR. Receiver operating characteristic curve analysis revealed that the AUC of CBDCA/BSA for predicting non-CR was higher than that of CBDCA-AUC. CBDCA/BSA shows greater potential for predicting CBDCA-induced emetic risk compared with CBDCA-AUC, which is the parameter in current antiemetic guidelines.
Nagoya University Graduate School of Medicine, School of Medicine
2021-11
eng
departmental bulletin paper
VoR
https://doi.org/10.18999/nagjms.83.4.773
http://hdl.handle.net/2237/0002001659
https://nagoya.repo.nii.ac.jp/records/2001659
10.18999/nagjms.83.4.773
https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/834.html
0027-7622
2186-3326
Nagoya Journal of Medical Science
83
4
773
785
https://nagoya.repo.nii.ac.jp/record/2001659/files/12_Ozone.pdf
application/pdf
578 KB
2021-12-03